Redefining
what’s treatable
Pioneering intracellular antibody therapies that reach beyond the limits of today’s medicines.
About Athlas Therapeutics
At Athlas Therapeutics, we are pioneering a new class of antibody medicines. Beyond the reach of conventional therapies, our IntraCell™ platform enables antibodies to gain access to cells — targeting disease mechanisms once considered untreatable.
Our lead candidate and patented technology, InflamAb, inhibits activation of the NLRP3 inflammasome — a key driver of chronic inflammation. By addressing inflammation at its source, we are aiming to transform the treatment landscape for chronic diseases and deliver better outcomes for patients.
The problem
Chronic inflammatory diseases are a leading cause of death globally, driving conditions such as cardiometabolic disorders, arthritis, glaucoma, inflammatory skin diseases and neurodegeneration.
While current therapies offer some relief, they often fall short — largely because the key drivers of inflammation are located inside cells, beyond the reach of conventional antibody therapies. As a result, the industry has relied on small molecules, which can enter cells but often lack the precision and long-lasting effects of antibodies.
This leaves patients facing frequent dosing and often limited long-term benefits.
Imprecise
Beyond the reach of conventional therapies
Frequent dosing
Limited long term benefits
Redefining the treatment of chronic inflammatory diseases
Athlas Therapeutics’ IntraCell™ platform enables antibodies to cross the cell membrane and engage key drivers of inflammation that were previously out of reach. Our lead candidate, InflamAb, is a dual-action antibody that directly inhibits the NLRP3 inflammasome — addressing the root cause of inflammation rather than just symptoms. Precisely delivered to inflamed cells, InflamAb offers greater durability than small molecules, allowing for less frequent dosing. Collectively, IntraCell™ and InflamAb hold broad potential to improve outcomes, slow disease progression, and redefine the treatment of chronic inflammatory diseases.
Chronic inflammatory diseases have become the leading cause of death worldwide
This is where our IntraCell™ technology makes a difference
By addressing inflammation at its source, InflamAb offers disease-modifying effects - preserving 70% of retinal and pancreatic beta cells and halting cardiovascular plaque build-up by 50%.
With IntraCell™ and InflamAb we are creating a new generation of antibody therapies that have the potential to revolutionise patient care.
The top half of our antibody IntraCell™ attaches to the receptor and then becomes internalised inside the cell. The bottom half of our antibody InflamAb then binds to a protein (NLRP3) inside the cell
This stops activation and progression of inflammation by stopping a "cytokine storm" (inhibiting IL-1beta and IL-18 cytokine secretion from the cell)
This leads to halting chronic inflammatory diseases like inflammatory eye conditions (glaucoma), inflammatory skin diseases and cardiometabolic conditions (coronary artery disease and diabetes).
As an antibody, it offers longer-lasting effects than small molecules, reducing the dosing frequency.
Our technology
InflamAb is a dual-action antibody designed to tackle both the signals and underlying drivers of inflammation. In preclinical models, it preserves up to 70% of retinal cells in glaucoma, protects 70% of pancreatic beta cells in diabetes, and slows cardiovascular plaque progression by 50%.
Delivered using our IntraCell™ platform, InflamAb enters inflamed cells with precision, minimizing off-target effects while maximizing impact. As an antibody, it offers longer-lasting effects than small molecules, reducing the dosing frequency.
IntraCell™ broadens the therapeutic potential of InflamAb - improves patient outcomes, lowers healthcare costs.
Our team
Dr Victoria McGilligan
PSA: Immunology expert specialising in antibody development and chronic inflammatory diseases. Victoria is passionate about translating cutting-edge science into impactful treatments for patients globally.
Dr Heather Spence
EL: Expertise in clinical development and stakeholder engagement to drive operational excellence and strategic growth.
Dr Oonagh Lynch
Specialising in managing and commercialising university-developed technologies in life and health sciences, Oonagh has 20+ years experience in technology transfer licensing and supporting entrepreneurs in building successful businesses
Dr Christine Power Business Advisor
Innovative scientist and advisor with 25+ years’ experience in therapeutic antibody development. Christine brings deep scientific insight, strategic guidance, and a proven track record of translating research into impactful therapies.
Dr Simon Barter Business Advisor
With extensive experience in the pharmaceutical industry, Simon specialises in driving commercialisation on a global scale. He brings first-hand knowledge of diverse healthcare markets, offering strategic guidance to businesses as they navigate and advance their technologies.
Interested in our research?
With IntraCell™ and InflamAb, we are creating a new generation of antibody therapies that have the potential to revolutionise patient care. Our IntraCell™ technology makes a difference. It is a platform enabling antibodies to penetrate the cell membrane and work inside the cytoplasm—unlocking targets that were previously considered unreachable.